The vascular endothelin system is not overactive in normotensive hemodialysis patients

Kidney International

Volumn 62, Issue 3, 2002, Pages 940-948

  Büssemaker, Eckhart ^a,b   Passauer, Jens ^a,b   Reimann, Doreen ^a,b   Schulze, Beate ^a,b   Reichel, Wolfgang ^a,b   Gross, Peter ^a,b  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b Kreiskrankenhaus Grossenhain   (Germany)

Author keywords

Chronic renal failure; Endothelin receptors; Forearm blood flow; Hemodialysis; Resistance vessels; Uremia

Indexed keywords

ADENOSINE; ANTIHYPERTENSIVE AGENT; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; NONSTEROID ANTIINFLAMMATORY AGENT; NORADRENALIN;

ADULT; ARTERY RESISTANCE; ARTERY TONE; ARTICLE; BLOOD PRESSURE; BLOOD VESSEL TONE; BRACHIAL ARTERY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INFUSION; FEMALE; FOREARM BLOOD FLOW; HEMODIALYSIS; HUMAN; HYPERTENSION; MALE; MEASUREMENT; PLASMA; PLETHYSMOGRAPHY; PRIORITY JOURNAL; PROTEIN FUNCTION; STRAIN GAUGE TRANSDUCER;

EID: 0036425958     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2002.00521.x     Document Type: Article

References (30)

1. 2+ channels. J Hypertens (Suppl 6):S188-S191, 1988
2. Haynes WG, Webb DJ: Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet 344:852-854, 1994
3. Gray GA, Webb DJ: The endothelin system and its potential as a therapeutic target in cardiovascular disease. Pharmacol Ther 72:109-148, 1996
4. Haynes WG, Ferro CJ, O'Kane KP, et al: Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation 93:1860-1870, 1996
5. Rubanyi GM, Polokoff MA: Endothelins: Molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev 46:325-415, 1994
6. Haynes WG, Strachan FE, Webb DJ: Endothelin ETA and ETB receptors cause vasoconstriction of human resistance and capacitance vessels in vivo. Circulation 92:357-363, 1995
7. Koyama H, Tabata T, Nishzawa Y, et al: Plasma endothelin levels in patients with uraemia. Lancet 1:991-992, 1989
8. Miyauchi T, Sugishita Y, Yamaguchi I, et al: Plasma concentrations of endothelin-1 and endothelin-3 are altered differently in various pathophysiological conditions in humans. J Cardiovasc Pharmacol 17(Suppl 7):S394-S397, 1991
9. Ottosson-Seeberger A, Ahlborg G, Hemsen A, et al: Hemodynamic effects of endothelin-1 and big endothelin-1 in chronic hemodialysis patients. J Am Soc Nephrol 10:1037-1044, 1999
10. Saito Y, Kazuwa N, Shirakami G, et al: Endothelin in patients with chronic renal failure. J Cardiovasc Pharmacol 17(Suppl 7):S437-S439, 1991
11. Kohan DE: Endothelins in the normal and diseased kidney. Am J Kidney Dis 29:2-26, 1997
12. Demuth K, Blacher J, Guerin AP, et al: Endothelin and cardiovascular remodelling in end-stage renal disease. Nephrol Dial Transplant 13:375-383, 1998
13. Nabokov AV, Amann K, Wessels S, et al: Endothelin receptor antagonists influence cardiovascular morphology in uremic rats. Kidney Int 55:512-519, 1999
14. Hand MF, Haynes WG, Webb DJ: Reduced endogenous endothelin-1-mediated vascular tone in chronic renal failure. Kidney Int 55:613-620, 1999
15. Cardillo C, Kilcoyne CM, Waclawiw M, et al: Role of endothelin in the increased vascular tone of patients with essential hypertension. Hypertension 33:753-758, 1999
16. Passauer J, Bussemaker E, Range U, et al: Evidence in vivo showing increase of baseline nitric oxide generation and impairment of endothelium-dependent vasodilation in normotensive patients on chronic hemodialysis. J Am Soc Nephrol 11:1726-1734, 2000
17. Smits P, Williams SG, Lipson DE, et al: Endothelial release of nitric oxide contributes to the vasodilator effect of adenosine in humans. Circulation 92:2135-2141, 1995
18. Verhaar MC, Strachan FE, Newby DE, et al: Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation 97:752-756, 1998
19. Ishikawa K, Ihara M, Noguchi K, et al: Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788. Proc Natl Acad Sci USA 91:4892-4896, 1994
20. Kohno M, Yasunari K, Murakawa K, et al: Plasma immunoreactive endothelin in essential hypertension. Am J Med 88:614-618, 1990
21. Herzog CA, Ma JZ, Collins AJ: Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 339:799-805, 1998
22. Hand MF, Haynes WG, Johnstone HA, et al: Erythropoietin enhances vascular responsiveness to norepinephrine in renal failure. Kidney Int 48:806-813, 1995
23. Morris ST, McMurray JJ, Spiers A, Jardine AG: Impaired endothelial function in isolated human uremic resistance arteries. Kidney Int 60:1077-1082, 2001
24. Koyama H, Tahara H, Shoji T, et al: Uremic serum contains humoral factor(s) larger than fifty kilodaltons which suppresses endothelin production in cultured endothelial cells. Contrib Nephrol 90:111-115, 1991
25. Cardillo C, Kilcoyne CM, Cannon RO III, Panza JA: Interactions between nitric oxide and endothelin in the regulation of vascular tone of human resistance vessels in vivo. Hypertension 35:1237-1241, 2000
26. Strachan FE, Crockett TR, Mills NL, et al: Constriction to ETB receptor agonists, BQ-3020 and sarafotoxin s6c, in human resistance and capacitance vessels in vivo. Br J Clin Pharmacol 50:27-30, 2000
27. Bode-Boger SM, Boger RH, Kuhn M, et al: Recombinant human erythropoietin enhances vasoconstrictor tone via endothelin-1 and constrictor prostanoids. Kidney Int 50:1255-1261, 1996
28. Vogel V, Kramer H J, Backer A, et al: Effects of erythropoietin on endothelin-1 synthesis and the cellular calcium messenger system in vascular endothelial cells. Am J Hypertens 10:289-296, 1997
29. Lebel M, Kingma I, Grose JH, Langlois S: Hemodynamic and hormonal changes during erythropoietin therapy in hemodialysis patients. J Am Soc Nephrol 9:97-104, 1998
30. Amann K, Munter K, Wessels S, et al: Endothelin A receptor blockade prevents capillary/myocyte mismatch in the heart of uremic animals. J Am Soc Nephrol 11:1702-1711, 2000